Myelodysplastic Syndrome: Competitive Landscape

Myelodysplastic Syndrome: Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics.

  • GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029.
  • MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies.
  • The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II.
  • Over the past decade, 1,229 clinical trials have been conducted in MDS.
  • During the past decade, partnerships were most prevalent in North America and Europe.
Scope

GlobalData’s Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.


  • Key Findings
  • Disease Overview
    • Disease Etiology
  • Epidemiology Overview
    • Epidemiology Overview - Diagnosed Prevalent Cases of MDS in 2024 and 2028
  • Treatment Overview
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in MDS
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Molecule type
    • Marketed Drug Profile - Novartis’s Gleevec/Glivec
    • Marketed Drug Profile - BMS’s Vidaza
    • Marketed Drug Profile - BMS’s Revlimid
    • Marketed Drug Profile - Geron’s Rytelo
    • Marketed Drug Profile - Otsuka Pharmaceutical’s Inaqovi/Inqovi
    • Marketed Drug Profile - BMS’s Reblozyl
    • Marketed Drug Profile - Servier Pharmaceutical’s Tibsovo
    • Marketed Drug Profile - Shorla Oncology’s Imkeldi
    • Marketed Drug Profile - Eisai ’s Dacogen/Dake
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Vidaza
    • Marketed Drugs - Time to Pricing and Reimbursement for Revlimid
    • Marketed Drugs - Time to Pricing and Reimbursement for Inqovi
    • Marketed Drugs - Time to Pricing and Reimbursement for Gleevec/Glivec
    • Marketed Drugs - Time to Pricing for Rytelo and Tibsovo
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Late-Stage Pipeline Drugs in MDS
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - PTSR and LoA in MDS & Oncology
    • Pipeline Drugs - PTSR and LoA in MDS
  • Clinical Trials Assessment
    • Clinical Trials in MDS - Historical Overview
    • Clinical Trials in MDS - Overview by Phase
    • Clinical Trials in MDS - Overview by Status
    • Clinical Trials in MDS - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in MDS - Trials with a Virtual Component
    • Clinical Trials in MDS - Geographic Overview
    • Clinical Trials in MDS - Single-Country and Multinational Trials by Region
    • Clinical Trials in MDS - Top Sponsors with Breakdown by Phase
    • Clinical Trials in MDS - Top Sponsors with Breakdown by Status
    • Clinical Trials in MDS - Overview by Endpoint Status
    • Clinical Trials in MDS - Overview by Race and Ethnicity
    • Trials in MDS - Enrollment Data
    • Clinical Trials in MDS - Overview of Sites by Geography
    • Clinical Trials in MDS - Top 20 Countries for Trial Sites
    • Clinical Trials in MDS - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for MDS
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in MDS by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in MDS
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in MDS
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in MDS
  • Appendix
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - PTSR and LoA Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings